newsAug 28, '14EmulTech launches INFINITY

R5 Formulation Development



R5 is a leading formulation development specialist, that focuses on the development and manufacturing of new medicines and clinical trial materials. The company is widely acknowledged as one of the leading providers of pharmaceutical dosage form development across Europe. It provides market leading formulation development, analytics and GMP services and guides clients through the processes of new medicine and material development for Phase I and Phase II clinical trials, maximizing budget effectiveness by minimizing experimentation without sacrificing quality levels.

R5 was acquired by leading pharmaceutical manufacturer, Aesica, in June 2010 and now forms one of Aesica’s three business units; R5 Formulation Development, Active Pharmaceutical Ingredients and Formulated Products.

Aesica is a leading full-service provider of contract research, development and manufacturing services for Formulated Products and Active Pharmaceutical Ingredients. The company develops long-term strategic partnerships with its clients, responds quickly and effectively to market demand and develops tailored solutions for specific requirements.

Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within Aesica enables it to provide primary and secondary contract manufacturing services to the highest possible regulatory standards. It is this full-service offer, its dedication to exceptional standards of service and its ability to deliver innovation and added value for its clients that truly sets Aesica apart from its counterparts.

For more information about R5 or Aesica please find the press release with EmulTech here or visit www.aesica-pharma.com.